From the CEO Archives | PainChek

From the CEO

Designed to be used by parents, family and carers - anyone that cares for young children who are unable to verbalise their pain.
...

The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer, to extend their PainChek® license to a designated home-based family carer, so that they can continue to conduct pain assessments with PainChek® in between their clinical consultations.
...

AI Technology Redefining Pain Assessment PainChek® provides carers across multiple clinical areas with three important new clinical benefits; 1.  The ability to identify the presence of pain, when pain isn’t obvious. 2.  To quantify the severity level of pain, when pain is obvious, and 3.  To monitor the impact of treatment to optimise overall care.
...

PainChek CEO & Managing Director Philip Daffas, recently gave an update to Canary Networks on the company's recent milestones and future plans.        To read more from PainChek's CEO, click here....

We are the world's first smartphone pain assessment and monitoring device - automatically detecting pain through facial recognition, empowering caregivers to accurately assess and manage pain.   https://www.youtube.com/watch?v=YRryN8iHUQM...

The Dementia Support Australia (DSA) “PainChek® in Practice” pilot study from September 2017 to April 2018 confirmed improvement in behavioural problems of clients with dementia.  PainChek® has now been rolled out nationwide across DSA’s 150 consultants caring for up to 5,000 people with dementia per annum.  Findings of the pilot were presented in the international HammondCare Dementia Conference, Sydney during June 7th-8th in Sydney and are being submitted to a peer reviewed journal later this year.  The project initially commenced in two states, WA and SA in September and October 2017. DSA referred-clients (from residential and community aged care providers) with a behavioural problem(s) were followed over the course of service. From September 2017 to April 2018, 118 clients aged 57-98 years old with various types of dementias or cognitive impairments including Alzheimer’s dementia and vascular dementia were included in the project. Pain was one of the most common contributing factors (53%) to these clients’ behaviours. In those with pain identified as a contributing factor and with medical history provided, 27 (84.4%) out of 32 clients had at least one painful condition - most commonly arthritis. There was also a significant positive clinical association between pain and clients’ behaviours. When pain...

New study published in the Journal of Pain Research on PainChek® confirms its accuracy. PainChek® demonstrated excellent performance with high sensitivity (96.1%), high specificity (91.4%) and high clinical accuracy (95.0%). High scores for clinical usefulness of the new technology (95.0%) demonstrates its value in the clinical setting to clinicians and carers. A third peer reviewed study has been published in the Journal of Pain Research which supports the clinical usefulness of PainChek®. In order to attract widespread clinical use, it is important to confirm both the accuracy and usefulness of the technology compared to existing methods for assessing pain. Clinicians will naturally ask themselves “Does the new tool work and is it as good as what we already use?” PainChek Ltd CEO Philip Daffas said “These results, combined with previous studies, support the clinical usefulness of PainChek® and further confirms its accuracy in detecting and quantifying pain in non-verbal people, such as those with advanced dementia. The findings also provide clinicians with great confidence for wider uptake of the tool in clinical practice in Australia and internationally”. The new study confirmed the accuracy (measurements of correct classification) and usefulness (measures of clinical decision making) of the tool based on 400 paired pain...

Dr Abbey is the developer and innovator behind the Abbey Pain Scale (APS) which has been the standard pain assessment tool used for people who cannot verbalise in Australia and overseas since 2004. Dr Abbey’s profile is highlighted below. “We are delighted to welcome Dr Abbey to the PainChek clinical advisory team. Jennifer brings a wealth of knowledge and experience in pain asserssment and will support our efforts to improve the quality of pain assessment and expand clinical indications for PainChek in Australia and overseas” said Philip Daffas CEO PainChek Ltd. In this advisory role, Dr Abbey will provide PainChek with support in expanding clinical indications including dementia care, palliative care, delirium and other cognitive impairment conditions liable to hamper pain identification and assessment. “I have a passion for continuous improvement in pain assessment and look forward to working with the PainChek team. I see PainChek as an evolutionary development of my past work, incorporating new technologies including smart devices and artificial intelligence that further improves the pain assessment process. There are many people who still do not have their pain assessed effectively. Our common goal is to ensure they do not suffer unnecessary pain” Dr Abbey commented. Dr Jennifer Abbey Profile: “Dr Jenny Abbey...

Philip Daffas talks to Jessica Amir on how PainChek works, the business model and future opportunities.   INTERVIEW LINK       PRESENTATION LINK Jessica Amir: Hello. I'm Jessica Amir for the Finance News Network. Joining me from PainChek Limited (ASX:PCK) is Managing Director and CEO Philip Daffas. Philip, welcome to the network. Philip Daffas: Thank you very much. Pleasure to be here. Jessica Amir: Thanks for coming. For new investors, just give us an introduction to PainChek as well as your novel app. Philip Daffas: Certainly. PainChek is a Australian-based company that's developed a very novel technology medical device that really addresses a major problem in healthcare, and that is the ability to assess pain for people who can't communicate effectively. We are on the market already. We already have sales in residential aged care, so we're actually up and running. And we have a number of clinical studies published, which shows the validity of the actual product. And the third most important thing -- we've got a team that can execute superbly. We've a strong team that actually has got good history in medical devices and healthcare. And me personally, I worked for Roche in the diabetes monitoring business for eight years, internationally and...

Australia's Good Design Awards, the highest honour for design innovation in Australia, were held at the Sydney Opera House on 17 May. PainChek™ received a prestigious Good Design Award® Gold Winner in the Social Impact category in recognition for outstanding design and innovation.   The Good Design Awards celebrate the best new products and services on the market, excellence in digital and communication design and reward emerging areas of design including business model innovation, social impact and design entrepreneurship. The Good Design Awards Jury said the PainChek™’s app is a “great product and beautiful integration of technology that will make a big difference to people’s lives. This system has real applicability and could be an incredibly impactful piece moving forward. Genuine issue and super promising with human application of machine learning to ease one of the many challenges of living with dementia. The system has been tested and peer reviewed and from a design and impact perspective is just plain excellent.” “Design to us is not just what a product looks like, but how it work” says PainChek CEO Philip Daffas. “Our vision was to create a simple, seamless and user-friendly app to make it easy to identify pain for those who don't have a...

Formerly ePat Technologies (ASX: EPT), medical device company PainChek (ASX: PCK) is on course to secure De Novo classification from the Food and Drug Administration (FDA) in the US — a relatively new process for novel devices which have not previously been classified. Read more.....